PMV Pharmaceuticals, Inc.
PMVP
Positions held
Your positionsPMVP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $112.51M | Enterprise value | $438,506 | Trailing P/E | — | Forward P/E | -1.54 |
| PEG | — | Price / book | 1.11 | Beta | 1.35 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -70.9% | ROA | -42.4% | Debt / equity | 0.00 |
| Current ratio | 7.70 | Free cash flow | -$43.82M | Analyst recommendation | none | Mean target | $4.20 |
| 52w high | $1.91 | 52w low | $1.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$18.1M | -$18.0M | -$18.0M | -$21.1M | -$21.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.9M | -$19.0M | -$19.2M | -$22.5M | -$22.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
2026-09-17 · These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
2026-09-16 · Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
2026-09-08 · PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
2026-09-01 · PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
2026-09-01 · Top Premarket Decliners
2026-09-01 · PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
2026-08-31 · PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering
2026-08-31 · PMV Pharma Announces Proposed Public Offering of Securities
2026-08-19 · PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
2026-08-14 · PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Price (daily)
Full chart · RSI · MACD · patterns